Sanofi and Regeneron Announce: An Introduction to the Phase 3 ODYSSEY OUTCOMES Study of the Antibody to PCSK9 SAR236553/REGN727

TO HEALTHCARE EDITOR:

 PARIS and TARRYTOWN, N.Y., Nov. 5, 2012 /PRNewswire/ -- Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) invite you to join this live webcast and Q&A session. The webcast will provide an introduction to the Phase 3 ODYSSEY OUTCOMES Study of the Antibody to PCSK9 SAR236553/REGN727 and will include the following speakers:

Robert Califf, M.D., Vice Chancellor of Clinical and Translational Research, Director of the Duke Translational Medicine Institute (DTMI), and Professor of Medicine in the Division of Cardiology at the Duke University Medical Center, USA

Christopher Cannon, M.D., Professor of Medicine at Harvard Medical School, Cardiovascular Division, Brigham and Women's Hospital, USA, and Member of the ODYSSEY Phase 3 Steering Committee

Jay Edelberg, M.D., Ph.D., Vice President,
Head of the PCSK9 Development & Launch Unit, Sanofi

Bill Sasiela, Ph.D., Vice President, Program Direction, Regeneron

Discussion will focus on the ODYSSEY OUTCOMES study design and rationale

What:

Live Webcast and Q&A Session:

When:

Monday, November 5th, 2012 at 6:00–7:00 am PT; 9:00–10:00 am ET; 3:00–4:00 pm CET

Where:

http://www.videonewswire.com/event.asp?id=90518

How:

Live over the Internet -- Simply log on to the web at the address above to register and view the event



Contact: 
For Media Inquiries:



Regeneron

Sanofi US

Peter Dworkin

Lori Lukus

(914) 847-7640

(908) 981-3876

peter.dworkin@regneron.com 

lori.lukus@sanofi.com


Sanofi International

Ingrid-Goerg-Armbrecht

+33 1 53 77 46 25

Ingrid.goerg-armbrecht@sanofi.com

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.  Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 

SOURCE Regeneron Pharmaceuticals; Sanofi

Read more on